Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development and commercialisation of novel therapeutic vaccines and gene-based therapies with a focus on oncology and neurotherapy. The Company was established in 1995 as a spin-out from Oxford University, and is listed on the London Stock Exchange.

The Company has a platform of gene delivery technologies, which are based on highly engineered viral systems. Oxford BioMedica also has in-house clinical, regulatory and manufacturing know-how. In oncology, the lead product candidate is TroVax^®, an immunotherapy for multiple solid cancers, which is licensed to sanofi-aventis for global development and commercialisation. A Phase III trial of TroVax^® in renal cancer is ongoing and sanofi-aventis is implementing a development plan for colorectal cancer. Oxford BioMedica's oncology pipeline includes a specific immunotherapy candidate, Hi-8^® MEL, for melanoma, which has completed two clinical trials. In neurotherapy, the Company's lead product, ProSavin^®, is expected to enter clinical development for Parkinson's disease in 2007. The neurotherapy pipeline also includes preclinical gene-based therapeutics for vision loss, motor neuron disease and nerve repair. In addition, the Company has a platform technology for therapeutic vaccines for infectious diseases.

The Company is underpinned by over 80 patent families, which represent one of the broadest patent estates in the field. The Company has a staff of approximately 75 split between its main facilities in Oxford and its wholly owned subsidiary, BioMedica Inc, in San Diego, California. Corporate partners include sanofi-aventis for TroVax^® and Wyeth for a targeted antibody therapy. The Company also has collaborations with Intervet, Sigma-Aldrich, Viragen, MolMed and Virxsys. Technology licensees include Merck & Co, Biogen Idec, GlaxoSmithKline and Pfizer.

Oxford BioMedica's proprietary LentiVector technology represents one of the most advanced gene delivery systems currently available. Licensed users include Biogen Idec, GlaxoSmithKline, Merck & Co and Pfizer. Oxford BioMedica also has a strategic alliance with Sigma-Aldrich to develop and commercialise LentiVector-based reagents for the research market. As a platform for gene therapy, it has broad utility for the treatment of chronic disorders such as neurodegenerative and ocular diseases.

Based on lentiviruses, LentiVector offers permanent gene transfer to a broad range of dividing and non-dividing cells, including neurons and retinal cells, in a stable and efficient fashion. The LentiVector technology is designed to be safe and non-toxic, as no viral genes are taken into the target cell.

The Company has shown in preclinical studies that gene expression using the LentiVector technology is maintained for more than 18 months. To date, Oxford BioMedica has not identified a situation where expression has ceased during the course of an experiment. Oxford BioMedica has established a broad pipeline of neurotherapy product candidates based on its LentiVector technology.

Sigma-Aldrich is a leading Life Science and High Technology company. Its biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. The Company has customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use its products. Sigma-Aldrich operates in 36 countries and has 7,600 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit its award-winning Web site at www.sigma-aldrich.com.